Currently nearly 300 clinical trials devoted to the COVVI-19 are underway worldwide to find a remedy. If for the time being, no drug has yet proven its effectiveness, the processing race is still continuing.
A clinical trial of remdsivir, the antiviral medication of the Gilead Sciences Inc laboratory, seems to show promising results in the treatment of coronavirus. The drug test carried out by the University of Chicago revealed that most of his patients had “rapid recovery of fever and respiratory symptoms” and that they had been unloaded in less than a week.
This study is based on 125 patients with the virus as part of two Gilead clinical trials, 113 of which were seriously sick and the Remèsivir was promising in the treatment of SRAS and severe acute respiratory syndrome, which are also caused by coronavirus.
RemDSIVIER is an experimental antiviral developed by Gilead Sciences and used to treat EBOLA virus disease and Marburg virus infections. This is why this molecule has been a part of the most promising and tested drugs, with chloroquine.
The action of the American laboratory Gilead Sciences jumped more than 13% Thursday evening at Wall Street in electronic exchanges after the closure, following information reporting positive preliminary results of clinical trials of its antiviral RemDesivir.
